Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bioficial Organs is a Louisville, Kentucky regenerative medicine and biofabrication company associated with Stuart K. Williams and the Cardiovascular Innovation Institute ecosystem. The company focuses on creating human tissues and organs for clinical therapeutics and for in vitro drug efficacy and toxicity testing using a patient’s own cells. Its core technological approach combines medical devices, regenerative medicine, bio-inks, and advanced 3D bioprinting to fabricate functional tissue constructs and ultimately transplantable organs. Publicly available information suggests it operates as an early-stage, preclinical venture and spinout-like effort rather than a commercial-stage therapeutics company. Bioficial Organs has also been cited as a collaborator in zero-gravity bioprinting work with Techshot and nScrypt.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bioficial Organs.